LCY Biosciences bought the plant for $4.34 million as PART of BioAmber’s court ordered liquidation process.
LCY Biosciences plans to zero in on succinic acid production first, the same product BioAmber specialized in, before expanding production to nutraceuticals.
getting ready for start up, as well as putting in place all of our supply and service agreements.”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.